NCT01271582View on ClinicalTrials.gov

Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

June 30, 2014

Study Completion Date

December 31, 2019

Conditions
Stage IV Colorectal CancerGastric Cancer
Interventions
DRUG

Irinotecan, 5FU, leucovorin

FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]

Trial Locations (5)

Unknown

Samsung Medical Center, Seoul

Hwasun Hospital, Jeonam

Korea Cancer Center Hospital, Seoul

National Cancer Center, Goyang

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT01271582 - Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients | Biotech Hunter | Biotech Hunter